Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Jeff Zacharias

Jeff Zacharias

New Hope Recovery Center, USA

Frank Galimidi

Frank Galimidi

New Beginnings Recovery Center, USA

Konstantin Slavin

Konstantin Slavin

University of Illinois , USA

Durodami Lisk

Durodami Lisk

Ministry of Health, USA

Peter Kaplan

Peter Kaplan

Johns Hopkins University, USA

Hemanth Rao

Hemanth Rao

The Neurological Institute, USA

Lucia M. Vaina

Lucia M. Vaina

Boston University College of Engineering, USA

Jennifer De Feo

Jennifer De Feo

Chicago School of Psychology, USA

Vascular Dementia 2019

About Conference


We invites all the participants from all over the world to attend 11th International Conference on Vascular dementia during Feb 15-16, 2019 at Amsterdam,Netherland with the Theme: Decoding Dementia ,which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Vascular dementia is defined as inadequate blood flow can damage and eventually kill cells anywhere in the body.

In Dementia, changes in intuition aptitudes here and there happen all of a sudden after strokes that piece real cerebrum veins. Vascular mind changes frequently exist together with changes connected to different sorts of dementia, including Alzheimer's sickness and dementia with Lewy bodiesDementia side effects might be most evident when they happen not long after a noteworthy stroke incorporates disarray, bewilderment, inconvenience talking or understanding discourse and vision misfortune.

The general multi infarct dementia showcase is portioned into North America, Asia Pacific, Europe, Latin America and MEA. Starting at 2015, North America held biggest piece of the pie regarding income inferable from the expanding frequencies of multi infarct dementia combined with expanding geriatric populace base. European market showed comparable qualities and took after North American multi infarct dementia advertises. Asia Pacific is required to develop at a high pace because of expanding mindfulness about anticipation of cerebrum strokes in this locale. Japan inferable from expanded geriatric base speaks to around over half of the dementia cases in Asia Pacific. The created countries, for example, Japan, Canada, France, Germany and U.S. are foreseen to witness positive development over the estimate time frame.

Various companies in the multi infarct dementia market are adopting several economic strategies such as collaborations, expansions and acquisitions to keep a strong position and gain advantage in the market. Some major companies in the market include Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Novartis Pharmaceutical Corporation, Pfizer, Inc. and Eisai, Inc.

Why to attend??

Vascular Dementia Conference is a unique forum to bring together worldwide distinguished academics in the field of Neuroscience and Neurology, Nutrition, Researchers, Public health professionals, Scientists, Academic scientists, Industry researchers, Scholars to exchange about state of the Research and Development.

Aim of this conference is stimulate new ideas for treatment that will be beneficial across the spectrum of Vascular Dementia. A Unique Opportunity for Advertisers and Sponsors at this International event.

 

Sessions/Tracks

Vascular Dementia 2019  has been planned and implemented in accordance with the accreditation requirementsand policies of the Accreditation Committee

If this educational activity will be accredited with CME and CPD Credits.

Attendance at this meeting will enable you to:

  •  
    • Be part of a rich scientific programme incorporating the latest developments in preclinical neurodegenerative diseases like Dementia and Alzheimer's Diseases
    • Understand the shift towards prevention and early diagnosis of neurodegenerative disease as the future of research in the field
    • Join key opinion leaders in discussing regulatory and ethical implications of this research in clinical practice.
    • Network with speakers and other leading experts across disciplines

Session on:

Session 1Dementia

Dementia is not a specific disease. It's an overall term that describes a wide range of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities. Alzheimer's diseaseVascular dementia, which occurs after a stroke, is the second most common dementia type. But there are many other conditions that can cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. Dementia is a syndrome that involves severe loss of cognitive abilities as a result of disease or injury. Dementia caused by traumatic brain injury is often static, whereas dementia caused by neurodegenerative disorders, such as Alzheimer's disease, is usually progressive and can eventually be fatal. Dementia can be grouped based on the part of brain being affected. it is roughly true that the earliest symptoms in "cortical" dementia include difficulty with high-level behaviors such as memory, language, problem-solving and reasoning; these functions tend to be less impaired in "subcortical" dementia.  Cortical dementia occurs because of damage in the cerebral cortex, the outer layer of the brain. They play a critical role in memory and language. The symptoms usually include severe memory lossAlzheimer's and Creutzfeldt-Jakob disease are two forms of cortical dementiaSubcortical dementia occurs due to the damage to the part of the brain beneath the cortex. The person suffering from it can show changes in their speed of thinking. Usually, people with subcortical dementia don't have forgetfulness and language problems. Parkinson's diseaseHuntington's disease, and HIV are two forms subcortical dementia.

Session 2: Vascular dementia

Vascular dementia is the broad term for dementia associated with problems of circulation of blood to the brain. There are a number of different types of Vascular dementia. Two of the most common are Multi-infarct dementia and Binswanger's disease. The multi-infarct dementia (MID) and vascular intellectual impedance is dementia caused by issues in the supply of blood to the mind, normally a progression of minor strokes. People with vascular dementiagive dynamic subjective hindrance, intensely or sub acutely as in mellow psychological debilitation, every now and again step-wise, after various cerebrovascular occasions (strokes). A few people may seem to enhance amongst occasions and decrease after more noiseless strokes. A quickly decaying condition may prompt demise from a stroke, coronary illness, or infection. Vascular dementia can be caused by ischemic or hemorrhagic infarcts influencing numerous mind regions, including the foremost cerebral supply route domain, the parietal projections, or the cingulate gurus.

Sessiom 3: Lewy body Dementia

Lewy body is also known as dementia with Lewy bodies, with Lewy body dementia is the second most common type of progressive dementia after Alzheimer's disease dementia. Protein deposits, called Lewy bodies, develop in nerve cells in the brain regions involved in thinking, memory and movement (motor control).

Lewy body dementia is also causes a progressive decline in mental abilities. The people with Lewy body dementia may experience visual hallucinations and changes in the alertness and attention and other effects include Parkinson's disease-like symptoms such as rigid muscles, slow movement and tremors.

Session 4: Amyloid Imaging in Dementia

Amyloid imaging is a technique performed in nuclear medicine. It uses PET ligands that allow in vivo detection of amyloid plaques, a core pathologic feature of Alzheimer disease  and dementia.

Session 5: Alzheimers Disease

Alzheimer's disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. AD begins slowly. It first involves the parts of the brain that control thought, memory and language. People with AD may have trouble remembering things that happened recently or names of people they know. A related problem, mild cognitive impairment (MCI), causes more memory problems than normal for people of the same age. Many, but not all, people with MCI will develop AD.

Session 6: Neurodegenerative Diseases

Degenerative nerve diseases affect many of your body's activities, such as balance, movement, talking, breathing, and heart function. Many of these diseases are genetic. Sometimes the cause is a medical condition such as alcoholism, a tumor, or a stroke. Other causes may include toxins, chemicals, and viruses. Sometimes the cause is not known.

Session 7: Brain diseases

Brain Diseases come in different forms of Infections, trauma, stroke, seizures, and tumors are some of the major categories of brain diseases. Here's an overview of various diseases of the brain

Session 8: Ageing and Dementia

Almost 42% of people over the age of 64 experience some form of memory loss. When there is no underlying medical condition causing this memory loss, it is known as "age-associated memory impairment," which is considered a part of the normal aging process.

  • Neuro-anatomical changes in ageing
  • Risk factors of cognitive decline
  • Granulovacuolar degeneration
  • Changes in cerebral cortical microvasculature
  • Advances of research in ageing and dementia

Session 9: Dementia Care Management

The developing number of Dementia patients prompts both approach, monetary and wellbeing association imperatives. Numerous social insurance frameworks have created case administration programs with a specific end goal to advance Alzheimer's patients and guardians care and administrations conveyance. Treatment of dementia relies on upon its cause. On account of most dynamic dementia, including Alzheimer's disease there is no cure and no treatment that moderates or stops its movement. In any case, there are medicating medicines that may briefly enhance side effects. Similar pharmaceuticals used to treat Alzheimer's are among the medications once in a while endorsed to help with side effects of different sorts of dementia. Non-sedate treatments can likewise reduce a few manifestations of Dementia. The increasing number of cognitively impaired older adults who exhibit wandering tendencies raises safety concerns. The purpose of the current study in neurology was to research the State-of the-Art in wearable technologies for persons with Alzheimer's disease and identify challenges unique to this population and lessons learned. Inclusion criteria specified systems that completed laboratory testing and were commercially available for usage by community-based Alzheimer's family caregivers.

  • Advances in dementia care management
  • Dementia care management program
  • Undernutrition and obesity in dementia
  • Advance care planning

Session 10: Dementia Nursing

People with vascular dementia have different mental element shortfalls that incorporate every memory hindrance, that influences the adaptability to discover new data or review data already learned, and one or extra of the ensuing side effects aphasia, apraxia, agnosia, or official brokenness to such an extent that the mental element shortages adversely affect social or action working with a major decrease in past abilities. Furthermore, people with dementia commonly experience the ill effects of comorbid conditions that extra confuse mind and block best results. Along these lines, creating caregiving techniques individuals with vascular dementia is pressing, given this expanding commonness and consequently the related weight that dementia places not just on the people, however on the parental figures, relations, and thusly the assets of the human services framework. Traditional perspectives bearing on geriatric nursing ordinarily paint a picture of the care as being moderate paced certain and less requesting than intense care. Be that as it may, care of the matured, and especially those with vascular dementia, is normally confounded, unusual, and flimsy.

Session 11: Treating Dementia

Early discovery and exact analysis are critical, as vascular dementia is at any rate halfway preventable .Ischemic changes in the cerebrum are irreversible, however the patient with vascular dementia can exhibit times of solidness or even gentle change. Since stroke is a basic piece of vascular dementia, the objective is to forestall new strokes. This is endeavored through decrease of stroke chance components, for example, hypertension, high blood lipid levels, atrial fibrillation, or diabetes mellitus. Meta-examinations have discovered that meds for hypertension are viable at counteractive action of pre-stroke dementia, which implies that hypertension treatment ought to be begun early .These drugs incorporate angiotensin changing over protein inhibitors, diuretics, calcium channel blockers, thoughtful nerve inhibitors, angiotensin II receptor opponents or adrenergic foes. Raised lipid levels, including HDL, were found to expand danger of vascular dementia. Ibuprofen is a medicine that is ordinarily recommended for counteractive action of strokes and heart assaults; it is likewise every now and again given to patients with dementia.

Session 12: Neuropharmacology

Neuropharmacology is an extremely wide locale of science that includes numerous parts of the sensory system from single neuron control to whole ranges of the cerebrum, spinal line, and fringe nerves. To better comprehend the premise behind medication advancement, one should first see how neurons speak with each other. This article will concentrate on both behavioral and atomic neuropharmacology; the real receptors, particle channels, and neurotransmitters controlled through medication activity and how individuals with a neurological issue advantage from this medication activity.

  • Neuroscience and neuropharmacology
  • Neurochemical interaction
  • Molecular neuropharmacology
  • Behavioral neuropharmacology
  • Advance research in neuropharmacology

Session 13: Novel therapeutics

Novel therapeutics is a standout amongst the most energizing uses of data preparing frameworks is in diagnostics and treatment. This is not astonishing, given that illness analysis is in its center a data handling undertaking that finishes with a choice. In numerous infections, the conclusion can be performed in singular cells.

  • Novel therapeutics strategies for Dementia
  • Novel therapeutics technology
  • Novel therapeutics molecule
  • Anti-dementia drugs
  • Novel drug target for the treatment of dementia

Session 14: Animal Models in Dementia

The animal models of dementia  and Alzheimer's disease for pre-clinical testing and clinical translation. Dementia is a clinical syndrome with abnormal degree of memory loss and impaired ability to recall events from the past often characterized by Alzheimer's disease.

  • Animal models of human cognitive aging
  • Genetics of translational models
  • Protein-protein interactions
  • Pre-clinical testing and clinical translation
  • Neurobehavioral Toxicology Testing

Session 15: Neuro Oncology and CNS

It is a branch of Medical Sciences majorly deals with Neuro tumors. Deals with Studies related to Brain and Spinal cord neoplasmsNeuro-oncology and Pediatric Neuro-oncology are the two different Concepts that differentiate the determining methodology of Neuro tumors. Neuro-oncology mainly includes especially related topics like Radiation therapyNeurosurgeryNeuroimaging, social, Psychological, Neuropathology and psychiatric aspects.

  • Spine Cancer and Spine Cancer Treatment
  • Glioblastoma
  • Meningioma
  • Brain Stem Tumors
  • Malignant Brain Cancers and Brain Metastasis
  • Pediatric Neuro Oncology
  • Astrocytoma
  • Neurotoxicity
  • Risk Factors
  • Radiation Therapy And Chemotherapy

 

Market Analysis

Neurodegenerative disorders, particularly Alzheimer’s disease (AD), other forms of dementia and Parkinson’s disease (PD), are among the biggest health care challenges of the 21st century. There are now over 250,000 dementia patients and 40,000 patients of Parkinson’s disease in the Netherlands. Because no treatments can stop these neurodegenerative disorders amid the backdrop of an aging population, numbers are expected to rise further quickly. This poses a direct threat to the sustainability of our entire health care system. The development of treatments that stop, prevent or at least slow down the degenerative processes is crucial to reduce future costs associated with neurodegenerative disorders and hence keep our health care system viable.

 

Neurodegenerative disorders share a profound pathophysiological and clinical complexity. For the majority of patients, multiple causes in concert lead to the development of disease, which unfolds over the course of years, probably decades. A careful clinical evaluation is the corner stone for a valid diagnosis of any neurodegenerative disorder. Moreover, it provides fundamental insight into the basic mechanisms that are critical for the development and validation of animal models and biomarkers. To date, treatment is limited to alleviation of symptoms, but our ultimate goal is to recognize disease before it manifests clinically, understand disease mechanisms and subsequently modify the disease process to prevent progression to a full blown disease state. This goal can only be achieved by improving early diagnostics, understanding clinical heterogeneity and mixed pathologies, and unraveling underlying mechanisms in patients and relevant model systems. We are in an excellent position to execute an integrative research program tailored to these aims. New technologies and in-house assets are the necessary prerequisites for success.

Our major assets are large and unique patient cohorts (Amsterdam Dementia Cohort: ~n=5000; Parkinson cohort: ~n=1000), large biobanks, extensive (multi-modal) brain imaging facilities and clinical trials. We have a strong tradition in translational research with excellent facilities. There is a longstanding and close collaboration with the Dutch brain bank and a history of research on post mortem tissue. Furthermore, we have ample experience in executing both complex, high-end clinical trials and large nationwide clinical trials. There is extensive expertise in clinical research, generation of well-characterized patient cohorts, clinical (endo)phenotyping (including advanced imaging using MRI, PET, EEG/MEG), as well as studies of (novel) biomarkers, neuroanatomy, neuropathology, transcriptomics, proteomics, gene finding, functional characterization, cellular and animal models. A major challenge of the program is to further emphasize synergistic approaches that can lead to breakthrough findings.

Past Conference Report

Vascular Dementia 2018

The 10th International conference on Vascular Dementia hosted by Conference Series LLC Ltd took place at Paris, France during Feb 22-23, 2018.

Active participation and generous response were received from the Organizing Committee Members, Editorial Board Members of Conference Series LLC Ltd Journals as well as from eminent scientists, talented researchers and young student community.

Researchers and students who attended from different parts of the world have made the conference one of the most successful and productive events in 2018 from Conference Series LLC Ltd.

The conference was marked by the presence of renowned scientists, talented young researchers, students and business delegates driving the three days event into the path of success with thought-provoking keynote and plenary presentations highlighting the theme “Exploring the challenges concerning excellence in Dementia research and care”

Conference Series LLC Ltd Ltd has taken the privilege of felicitating Vascular Dementia 2018 Conference Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this event.

Conference Series LLC Ltd, on behalf of the conference sponsor, appreciates all the participants who put their efforts for this event and sincerely wishes them success in future endeavors.

The esteemed guests, Keynote speakers, well-known researchers, and delegates shared their innovative research and vast experience through their fabulous presentations at the podium of grand Vascular Dementia 2018 Conference.

We are glad to inform that all accepted abstracts for the conference have been indexed in Conference Series LLC  Ltd“Journal of Alzheimer’s Disease & Parkinsonism” as a special issue.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums.

We sincerely thank the Organizing Committee Members for their gracious presence, support and assistance towards the success of Vascular Dementia 2018.

With the unique feedbacks from the conference, Conference Series LLC Ltd would like to announce the commencement of the 11th International Conference on Vascular Dementia during February 15-16, 2019 Amsterdam, Netherlands

Let us meet again @ Vascular Dementia 2019

 


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date February 15-16, 2019

For Sponsors & Exhibitors

sponsors@conferenceseries.com

Speaker Opportunity

Supported By

Journal of Alzheimers Disease & Parkinsonism Journal of Neurological Disorders Brain Disorders & Therapy

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by